When was MDacne founded?

MDacne was founded in 2009 and raised its 1st funding round 8 years after it was founded.

Where is MDacne located?

MDacne is headquartered in San Francisco, United States. It is registered at 548 MARKET ST STE 86774,SAN FRANCISCO,CA,94104.0,0.

How many employees does MDacne have?

As of Jul 01, 2024, the latest employee count at MDacne is 7.

Is MDacne a funded company?

MDacne is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2017.

When was the latest funding round of MDacne?

MDacne's latest funding was a $***** Seed round on 2017, with participation from 1 investor. Its primary sector is Dermatology. In United States, the Dermatology sector has seen $172M in funding in 2026 to date.

Where does MDacne rank among its competitors?

MDacne ranks 529th amongst 2536 active competitors, of which 866 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of MDacne?

MDacne's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

MDacne - 2026 Company Profile, Team, Funding & Competitors

MDacne is a seed company based in San Francisco (United States), founded in 2009 by Yoram Harth and Oded Harth. It operates as a Provider of personalised treatment for acne. MDacne has raised $120K in funding. The company has 2536 active competitors, including 866 funded and 619 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Provider of personalised treatment for acne. It offers a custom acne treatment solution through their app, analyzing skin and delivering personalized treatment kits whcih consist of dark spot remover, mask, patches, cleanser, and others.

Website: www.mdacne.com/
Social
Email ID: *****@mdacne.com
Part Of
Registered Address: 548 MARKET ST STE 86774,SAN FRANCISCO,CA,94104.0,0

Key Metrics

Founded Year

2009

Location

San Francisco, United States

Stage

Seed

Total Funding

$120K in 1 round

Latest Funding Round

Seed, 2017, $*****

Investors

REDO Ventures & 2 more

Ranked

529^th among 2536 active competitors

Employee Count

7 as on Jul 01, 2024

Similar Companies

LEO Pharma & 152 more

View MDacne's full profile

MDacne is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MDALGORITHMS INC. CIN: 32076395402 , United States, Active	Oct 22, 2020	-	-	-

MDacne has raised a total funding of $120K over 1 round. Its latest funding round was a Seed round on 2017 for $*****. 1 investor participated in its latest round. MDacne has 3 institutional investors.

Here is the list of recent funding rounds of MDacne:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2017	4593	Seed	9707	6875	3842	8457

Access funding benchmarks and valuations. Sign up today!

View details of MDacne's funding rounds and investors

The founders of MDacne are Yoram Harth and Oded Harth.

Here are the details of MDacne's key team members:

Yoram Harth: Co-Founder of MDacne and founder of 1 other company.
Oded Harth: Co-Founder & CEO of MDacne.
Contact Info: 1 email address

View details of MDacne's Founder profiles and Board Members

MDacne's employee count trend

MDacne has 7 employees as of Jul 24. Here is MDacne's employee count trend over the years:

Uncover MDacne's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MDacne include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of MDacne, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	72/100
9th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
529th	MDacne 2009, San Francisco (United States), Seed	Provider of personalised treatment for acne	$120K	REDO Ventures, Y Combinator & 1 others	48/100